Diagnostic Value of Cytomegalovirus IgM Antibodies at Birth in PCR-Confirmed Congenital Cytomegalovirus Infection

• Published in: International journal of molecular sciences Vol. 20; no. 13; p. 3239
• Main Authors: Ohyama, Shohei, Fujioka, Kazumichi, Fukushima, Sachiyo, Abe, Shinya, Ashina, Mariko, Ikuta, Toshihiko, Nishida, Kosuke, Matsumoto, Hisayuki, Nakamachi, Yuji, Tanimura, Kenji, Yamada, Hideto, Iijima, Kazumoto
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.07.2019; MDPI
• Subjects: Age; Antibodies, Viral - metabolism; Birth weight; Communication; Cytomegalovirus; Cytomegalovirus - genetics; Cytomegalovirus - immunology; Cytomegalovirus Infections - congenital; Cytomegalovirus Infections - diagnosis; Cytomegalovirus Infections - immunology; DNA Viruses - genetics; DNA, Viral - analysis; Female; Humans; Immunoglobulin M - metabolism; Immunoglobulins; Infant; Infant, Newborn; Infections; Laboratories; Male; Microcephaly; Mothers; Newborn babies; Patients; Predictive Value of Tests; Prospective Studies; Urine; Urine - virology; Viral infections; Japan; quantitative real-time PCR; cytomegalovirus IgM antibody; congenital cytomegalovirus infection
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms20133239

Although cytomegalovirus (CMV) DNA detection in urine is the standard method for diagnosing congenital cytomegalovirus infection (CCMVI), polymerase chain reaction (PCR) is not comprehensively available. Currently, the efficacy of CMV-specific IgM (CMV-IgM) and CMV-specific IgG (CMV-IgG) detection remains unclear. To determine the sensitivity and specificity of CMV-specific antibodies at birth, we investigated CMV-IgM and CMV-IgG titers in CCMVI cases and non-CCMVI controls, with confirmed diagnoses by urine quantitative real-time PCR within 3 weeks after birth. We included 174 infants with suspected CCMVI in whom serological testing was performed within the first 2 weeks after birth during 2012–2018. We classified the participants into a CCMVI group (n = 32) and non-CCMVI group (n = 142) based on their urine PCR results. The CMV-IgM-positive rate was 27/32 (84.4%) in the CCMVI group, compared with 1/142 (0.7%) in the non-CCMVI group (p < 0.0001). The positive CMV-IgG rates were 32/32 (100%) in the CCMVI group and 141/142 (99.3%) in the non-CCMVI group. The positive predictive value for CMV-IgM was high at 96.4% (27/28). This value may be sufficient for clinical use, especially in settings with limited resources where PCR is unavailable. However, CCMVI screening by CMV-IgM alone appears insufficient because of the considerable number of false-negative cases.